Conference Description:

With new clinical data and more ground-breaking advancements in the technology underpinning microbiome research, Europe's leading microbiome organisations are paving the way for drug development!

Join us at the 8th Microbiome Movement- Drug Development Summit Europe where we will cover the most exciting progress in the microbiome world, from expanded analytics and larger-scale manufacturing to the most pressing challenges from translation to regulations. In January, 150+ microbiome innovators will be united in Barcelona for the flagship meeting for European microbiome-based therapeutic developers.

We are bringing together microbiome trailblazers across industry, academia and investors to share their insights across autoimmune disorders, oncology, lung disease, hepatic disease, women's health and more! Now with new interactive sessions such as a reverse pitch opportunity, technology showcase, poster session and guided networking. This unmissable event will provide you with the opportunity to transform your drug development pipelines and meet like-minded individuals to help you along the way.



Time: 7:30 AM - 5:00 PM

Prices:
Conference + Pre-Conference Focus Day (Industry): EUR 3297.00,
Conference Only (Industry): EUR 2399.00,
Conference +Pre-Conference Focus Day (Academic): EUR 2697.00,
Conference Only (Academic): EUR 1999.00,
Conference + Pre-Conference Focus Day (Solution Provider): EUR 4597.00,
Conference Only (Solution Provider): EUR 3399.00

Speakers: Ada Lam, Lead Research Analyst, Beacon Targeted Therapies, Amelie Baud Research group leader Centre For Genomic Regulation(CRG), Amine Zorgani Founder Microbiome Mavericks, Ana Montalban-Arques Chief Executive Officer and Co-founder Recolony, Annelise Soulier Co-Founder and Chief Scientific Officer Neobe Therapeutics, Antonio LC Gomes Principal Scientist Xbiome Co. Ltd., Aran Singanayagam Medical Research and Council Clinician Scientist Fellow Imperial College London, Benjamin Hadida Chief Executive Officer Exeliom Biosciences, Carole Schwintner Chief Technology Officer Maat Pharma, Chrysi Sergaki Principal Investigator - Microbiome Group Leader Medicines and Healthcare products Regulatory Agency, Claudio Hidalgo Cantabrana CEO Microviable Therapeutics, Denise Kelly Investment Advisor Seventure Partners, Diana Gutierrez Fernandez Chief Technology Officer Telum Therapeutics, Elran Haber CEO Biomica Ltd., Eric J. C. Gálvez Bioinformatician Data Scientist Roche, Gabriel Leventhal Chief Scientific Officer PharmaBiome, Herve Affagard Founder and Chief Executive Officer Maat Pharma, Jakob Krause Haaber VP, CRISPR and Delivery Technologies SNIPR Biome, James McIlroy Founder and Chief Executive Officer EnteroBiotix, Johan Van Hylckama Vlieg Chief Scientific Officer and Co-founder Freya Biosciences ApS, Juan Basterra CEO and Co-founder, Director general Mikrobiomik, Karine Roget, Chief Scientific Officer, Nexbiome, Katja Conrath, Chief Scientific Officer, MRM Health, Maria Lluch Senar, Founder and Chief Scientific Officer, Pulmobiotics, Massimo Marzorati, Chief Executive Officer, ProDigest, Matthew Robinson, Senior Vice President - Research, Microbiotica, Mohan Iyer, General Partner, Indie Bio, Nastassia Knödlseder, Universitat Pompeu Fabra, Nathalie Corvaia, Chief Scientific Officer, Maat Pharma, Nik Sharma, CEO and co-founder, BioCortex, Patricia Del Rio, Director of Business Development, Mikrobiomik, Pedro De Sampaio, Co-founder and Chief Executive Officer, Neobe Therapeutics, Sarah Luppino, Investor, M Ventures, Shahram Lavasani, Founder and Chief Executive Officer, ImmuneBiotech AB, Sou Miyake, Director of Investment and Business Development, CSB Group, Staffan Srömberg, Chief Executive Officer, Infant Bacterial Therapeutics AB, Todd Krueger, President and CEO, AOBiome, Tomas de Wouters, Co-Founder and Chief Executive Officer, PharmaBiome, Vladislav Krupalnik, Chief Scientific Officer, Epeius Pharma, Yemi Adesokan, Chief Executive and Scientific Officer, Gnubiotics Sciences